Guardant Health
GH
#2708
Rank
NZ$8.63 B
Marketcap
$69.96
Share price
-5.84%
Change (1 day)
132.25%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Guardant Health (GH) - Cash on Hand

Cash on Hand as of December 2024 : NZ$1.46 Billion

According to Guardant Health 's latest financial reports the company has NZ$1.46 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Guardant Health - Cash on Hand chart (from 2017 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31NZ$1.84 B16.02%
2022-12-31NZ$1.59 B16.63%
2021-12-31NZ$1.36 B-45.1%
2020-12-31NZ$2.48 B220.45%
2019-12-31NZ$0.77 B24.28%
2018-12-31NZ$0.62 B100.43%
2017-12-31NZ$0.31 B126.61%
2016-12-31NZ$0.13 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
NZ$1.60 B 9.80%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.24 B-83.31%๐Ÿ‡บ๐Ÿ‡ธ USA